<DOC>
	<DOC>NCT00806897</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to gain practical experience with once daily Levemir® administration in type 2 diabetes patients who were previously treated with NPH insulins (e.g. Protaphane®) as basal insulin as part of their IIT under normal clinical practice conditions in Lithuania</brief_summary>
	<brief_title>Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Type 2 diabetic subjects on intensive insulin treatment (IIT) Eligibility for once daily insulin detemir administration Informed consent obtained before any observationrelated activities Known or suspected allergy to insulin detemir Subjects previously enrolled in the observation Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>